IAP BIR domain binding compounds

Details IAP BIR domain binding compounds IAP BIR domain binding compounds

2007-03-16

2009-08-25

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S016700, C514S017400, C514S397000, C514S422000, C514S423000, C424S130100, C435S029000, C530S328000, C530S329000

Reexamination Certificate

active

07579320

ABSTRACT:
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or IIor a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.

REFERENCES:
patent: 6110691 (2000-08-01), Wang et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6992063 (2006-01-01), Shi
patent: 7041784 (2006-05-01), Wang et al.
patent: 7094758 (2006-08-01), Wang et al.
patent: 7229617 (2007-06-01), Nasoff et al.
patent: 7244851 (2007-07-01), Cohen et al.
patent: 7309792 (2007-12-01), Harran et al.
patent: 2004/0180828 (2004-09-01), Shi
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2005/0234042 (2005-10-01), Palermo et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0211627 (2006-09-01), Reed et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2007/0032437 (2007-02-01), Shi et al.
patent: 2007/0042428 (2007-02-01), Springs et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: 2007/0219140 (2007-09-01), Laurent et al.
patent: 2008/0069812 (2008-03-01), Boudreault et al.
patent: 2008/0089896 (2008-04-01), Wang et al.
patent: 2008/0207525 (2008-08-01), Boudreault et al.
patent: 2491041 (2004-01-01), None
patent: 2 582 734 (2005-09-01), None
patent: 2 560 162 (2005-10-01), None
patent: 2 574 040 (2006-02-01), None
patent: 61183297 (1986-08-01), None
patent: 04208299 (1992-07-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/030959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/086470 (2003-10-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 02/26775 (2004-04-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/074989 (2005-08-01), None
patent: WO 2005/084317 (2005-09-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/010118 (2006-01-01), None
patent: WO 2006/017295 (2006-02-01), None
patent: WO 2006/069063 (2006-06-01), None
patent: WO 2006/113376 (2006-10-01), None
patent: WO 2006/122408 (2006-11-01), None
patent: WO 2006/128455 (2006-12-01), None
patent: WO 2006/133147 (2006-12-01), None
patent: WO 2007/048224 (2007-05-01), None
patent: WO 2007/075525 (2007-07-01), None
patent: WO 2007/101347 (2007-09-01), None
patent: WO 2007/104162 (2007-09-01), None
patent: WO 2007/106192 (2007-09-01), None
patent: WO 2007/131366 (2007-11-01), None
patent: WO 2007/136921 (2007-11-01), None
patent: WO 2008/014229 (2008-01-01), None
patent: WO 2008/014236 (2008-01-01), None
patent: WO 2008/014238 (2008-01-01), None
patent: WO 2008/014240 (2008-01-01), None
patent: WO 2008/014252 (2008-01-01), None
patent: WO 2008/014263 (2008-01-01), None
patent: WO 2008/016893 (2008-02-01), None
patent: WO 2008/045905 (2008-04-01), None
patent: WO 2008/057172 (2008-05-01), None
patent: WO 2008/067280 (2008-06-01), None
patent: WO 2008/073306 (2008-06-01), None
patent: WO 2008/079735 (2008-07-01), None
patent: WO 2008/085610 (2008-07-01), None
patent: WO 2008/128121 (2008-10-01), None
patent: WO 2008/134679 (2008-11-01), None
patent: WO 2008/144925 (2008-12-01), None
GenBank Accession No. NP—776511, Accessed Jul. 1, 2008.
GenBank Accession No. Q13490, Accessed Jul. 1, 2008.
GenBank Accession No. CAB95312, Accessed Jul. 1, 2008.
Glover, Constance J. et al,“A High-Throughput Screen for Identification..” Analytical Biochemistry 320 (2003), pp. 157-169.
Kipp, R.A. et al, Molecular Targeting of Inhibitor of Apoptosis Protein.., Biochemistry, vol. 41, No. 23, pp. 7344-7349 (2002).
Li, Lin et al, “A Small Molecule Smac Mimic Potentiates TRAIL-and..”, Science, vol. 305, pp. (2004).
Oost, Thorsten K. et al, “Discovery of Potent Antagonists of the Antiapoptotic..” Journal of Medicinal Chemistry, pp. A-J (2004).
Sun, Yaiying et al “Structure-Based Design, Synthesis and Biochemical Testing of Novel” Bioorganic & Medicinal Chemistry Letters 15 (2005) 793-797.
Arnt et al.,J. Biol. Chem., “Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in Situ,” 277(46): 44236-44243.
Bertrand et al.,Mol. Cell, “cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination,” 30: 689-700 (2008).
Bucher et al.,Helv. Chim. Acta., 78(4):935-46 (1995).
Chai et al.,Nature, “Structural and biochemical basis of apoptotic activation by Smac/DIABLO,” 406: 855-62 (2000).
Chauhan et al.,Blood, “Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM),” 109(3): 1220-7 (2007).
Chen et al.,Bioorg. Med. Chem. Lett., “Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein,” 16(22): 5805-5808 (2006).
Eckelman et al.,Cell Death Differ., “The mechanism of peptide-binding specificity of IAP BIR domains,” 15(5): 920-8 (2008).
Elmore et al.,Annual Rep. Med. Chem., “Inhibitors of Anti-apoptotic Proteins for Cancer Therapy,” 40: 245-62 (2006).
Franklin et al.,Biochemistry, “Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP),” 42: 8223-31 (2003).
Fulda et al.,Nature Medicine, “Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo,” 8: 808-15 (2002).
Gao et al.,J. Biol. Chem., “A dimeric Smac/Diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo,” 282(42): 30718-27 (2007).
Haining et al.,Proc. Natl. Acad. Sci. USA, “The proapoptotic function of Drosophila HID is conserved in mammalian cells,” 96(9): 4936-41 (1999).
Kipp et al.,Biochemistry, “Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners,” 41: 7344-9 (2002).
Li et al.,Science, “A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death,” 305(5689): 1471-4 (2004).
Liu et al.,Nature, “Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain,” 408: 1004-8 (2000).
Marik et al.,J. Peptide. Res., “Synthesis and effect of shortened oostatic decapeptide (TMOF) analogs with isosteric structures on reproduction of Neobellieria bullata,” 57(5): 401-8 (2001).
McCarthy et al.,J. Biol. Chem., “Apoptosis induced by Drosophila reaper and grim in a human system. Attenuation by inhibitor of apoptosis proteins (cIAPs),” 273(37): 24009-15 (1998).
Nikolovska-Coleska et al.,Anal. Biochem., “Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization,” 332: 261-273 (2004).
Nikolovska-Coleska et al.,J. Med. Chem., “Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database,” 47(10): 2430-40 (2004).
Nikolovska-Coleska et al.,Anal. Biochem., “Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains,” 374(1): 87-98 (2008).
Oost et al.,J. Med. Chem., “Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer,” 47(18): 4417-26 (2004).
Park et al.,Bioorg. Med. Chem. Lett., “Non-peptidic small molecule inhibitors of XIAP,” 15(3): 771-5 (2005).
Petersen et al.,Cancer Cell, “Autocrine TNFalp

Affiliated with

Also associated with

Rating

IAP BIR domain binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IAP BIR domain binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAP BIR domain binding compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4098020